As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

The management of pulmonary hypertension has already incorporated ... act principally through vasodilatation of the pulmonary arterial circulation through well-delineated mechanisms, although ...

Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant ...

and it’s different from the commonly known hypertension that is just basically high blood pressure. This one is high blood ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

Each year, 500 to 1,000 people in the U.S. are diagnosed with pulmonary arterial hypertension (PAH), a progressive and often under-detected disease. To address the significant impact of this disease ...

Pulmonary arterial hypertension (PAH) is one of five types of pulmonary hypertension. It happens when the blood vessels in your lungs narrow and scar so much that it’s hard for blood to move ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors ---- Advancement of IkT-001Pro into a ...

Liquidia Technologies ( (LQDA) ) has released its Q3 earnings. Here is a breakdown of the information Liquidia Technologies presented to its ...